about
Identification of a novel pro-apoptotic role of NF-κB in the regulation of TRAIL- and CD95-mediated apoptosis of glioblastoma cellsIn vitro ultramorphological assessment of apoptosis induced by zerumbone on (HeLa).Phase II trial of mapatumumab, a fully human agonistic monoclonal antibody that targets and activates the tumour necrosis factor apoptosis-inducing ligand receptor-1 (TRAIL-R1), in patients with refractory colorectal cancerTRAIL mutant membrane penetrating peptide alike-MuR6-TR enhances the antitumor effects of TRAIL in pancreatic carcinoma both in vitro and in vivo.A Phase 1b/2 trial of mapatumumab in patients with relapsed/refractory non-Hodgkin's lymphoma.TRAIL (TNF-related apoptosis-inducing ligand) regulates adipocyte metabolism by caspase-mediated cleavage of PPARgamma.How to target apoptosis signaling pathways for the treatment of pediatric cancersImmunotherapy for liver tumors: present status and future prospects.Apoptosis pathways and their therapeutic exploitation in pancreatic cancer.Initial testing (stage 1) of mapatumumab (HGS-ETR1) by the pediatric preclinical testing program.Tumor Necrosis Factor-related apoptosis-inducing ligand (TRAIL) Receptor-1 and Receptor-2 agonists for cancer therapy.Emerging anticancer therapeutic targets and the cardiovascular system: is there cause for concern?Emerging monoclonal antibodies and related agents for the treatment of chronic lymphocytic leukemia.Cell death controlling complexes and their potential therapeutic role.A randomized, double-blind, placebo-controlled phase II study to assess the efficacy and safety of mapatumumab with sorafenib in patients with advanced hepatocellular carcinoma.BAG3 induction is required to mitigate proteotoxicity via selective autophagy following inhibition of constitutive protein degradation pathways.RIP1 is required for IAP inhibitor-mediated sensitization for TRAIL-induced apoptosis via a RIP1/FADD/caspase-8 cell death complex.Targeting death receptors: is this trail still hot?RIP1 protein-dependent assembly of a cytosolic cell death complex is required for inhibitor of apoptosis (IAP) inhibitor-mediated sensitization to lexatumumab-induced apoptosis.Targeting apoptosis signaling in pancreatic cancerTRAIL is involved in the tumoricidal activity of mouse natural killer cells stimulated by Newcastle disease virus in vitro.
P2860
Q24319961-0024F6AD-40F9-4710-A305-E69768AEF9F6Q33426319-6B4D2AD3-CA94-444D-A412-9480DAF71453Q33658593-27735B9A-65D6-4769-8FE4-BC4BF4E0E195Q33674881-089D6C3E-0ACD-44B1-9C52-980BCD4DF769Q34433792-3F0C5AF5-E2DC-4C0B-817C-33FC6C8E1ECAQ36586540-8497355B-3573-4936-8D11-C3F10B6CCB2DQ36610528-044D15A4-3836-4985-B76A-942CBCC5D428Q37144014-F0B40B1C-C281-4478-979F-7280699B3DCDQ37453523-FD21D4F7-C378-422F-A049-BA2681944FCFQ37480185-F6582EAC-A656-4B1F-89A3-C345BD44D186Q37621564-9D0986B8-029E-4A21-9E92-F6D8582D8E0FQ37723147-3C9DF8F8-7D35-4138-A212-8BA9D6655234Q38068494-549458AC-2900-4C95-96B2-ECBD9E9F4490Q38260863-1DCFB902-2F43-492B-AF28-3D282F766E0AQ38708598-11D7D456-7CF9-4220-8FCA-B76AFEA56859Q39156205-81D121FF-9631-4221-B13E-9B291788BD44Q39298005-D421913F-473B-41AB-9CA6-52B592EDDD7BQ40033141-3F1E7637-5481-45F2-BB3A-0A1AF8CF39A6Q41311490-85DE8586-036B-4FAF-9198-99128A8B85D4Q42040100-3D5B5931-376F-4AEE-A462-4D0B4AE05C4FQ42275614-85E4050B-4F6F-48F6-8DC1-C40CBB33BF7C
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Trail receptors: targets for cancer therapy.
@en
Trail receptors: targets for cancer therapy.
@nl
type
label
Trail receptors: targets for cancer therapy.
@en
Trail receptors: targets for cancer therapy.
@nl
prefLabel
Trail receptors: targets for cancer therapy.
@en
Trail receptors: targets for cancer therapy.
@nl
P1476
Trail receptors: targets for cancer therapy.
@en
P2093
Robin C Humphreys
Wendy Halpern
P304
P356
10.1007/978-1-4020-6554-5_7
P407
P577
2008-01-01T00:00:00Z